Stockscreener 앱 받기
19.14
3.09%
-0.61
전일 마감가:
$19.75
열려 있는:
$19.9
하루 거래량:
2.18M
Relative Volume:
1.78
시가총액:
$1.04B
수익:
-
순이익/손실:
$-883.08M
주가수익비율:
-0.0574
EPS:
-333.4782
순현금흐름:
$-150.65M
1주 성능:
-7.04%
1개월 성능:
+47.23%
6개월 성능:
+41.57%
1년 성능:
-58.57%
1일 변동 폭
$17.67
$19.90
1주일 범위
$17.67
$21.00
52주 변동 폭
$6.50
$56.80
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
19.14 | 1.04B | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-30 | 개시 | Jefferies | Buy |
| 2026-03-19 | 개시 | Wells Fargo | Overweight |
| 2026-01-09 | 개시 | Citigroup | Buy |
| 2025-12-17 | 개시 | TD Cowen | Buy |
| 2025-12-09 | 개시 | JP Morgan | Overweight |
| 2025-11-25 | 재개 | Wedbush | Neutral |
| 2025-10-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | 업그레이드 | Stifel | Hold → Buy |
| 2025-06-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Form 4 Vor Biopharma Inc For: 9 July By Investing.com - Investing.com Canada
Vor Biopharma (VOR) director receives 42,658 stock options at $20.10 strike - Stock Titan
Vor Biopharma Inc. Files Form 8-K With SEC – Company Details, Stock Info, and Emerging Growth Status - Minichart
Vor Biopharma Adds Industry Veteran David Zaccardelli to Board - TipRanks
Vor Bio appoints David Zaccardelli to board of directors By Investing.com - Investing.com Canada
David Zaccardelli joins Vor Biopharma (NASDAQ: VOR) board after Levin exit - Stock Titan
Vor Bio adds Verona Pharma veteran David Zaccardelli to board - Stock Titan
Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes - Seeking Alpha
Vor Biopharma Sees Insider Stock Selling - 富途牛牛
Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next - simplywall.st
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Why Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's Next - Yahoo Finance
3 Reasons Vor Biopharma (VOR) Looks Pricey On Russell Index Inclusion - Sahm
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2500 Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Value Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Value Benchmark Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2000 Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000E Growth Benchmark - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell Microcap Index - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 2500 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBIT forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
Vor Biopharma Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Pre-Revenue Stage - dars.gov.et
Vor Biopharma, Inc. Actuals & Estimates (NASDAQ:VOR) - TradingView
Vor Biopharma (VOR) Surges 8% as Shares Test Key Resistance at $16.95Imbalance Zone - dars.gov.et
Vor Biopharma | 4: Statement of changes in beneficial ownership of securities-Director RA CAPITAL MANAGEMENT, L.P.moomoo - Moomoo
VOR Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Vor Biopharma Inc. – NASDAQ:VOR - TradingView
VOR Q1 2026 Earnings: Severe EPS Miss Highlights Clinical-Stage Biotech ChallengesSegment Revenue Breakdown - dars.gov.et
Vor Biopharma Inc (VOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vor Biopharma Inc (VOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VOR Stock Price, Quote & Chart - ChartMill
Vor Biopharma Inc (VOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vor Biopharma Inc (VOR) Institutional Confidence - TradingKey
Vor Biopharma Inc (VOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vor Biopharma Inc (VOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vor Biopharma Inc (VOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vor Biopharma Q1 2026 Earnings: Deep EPS Miss Amid Ongoing R&D Investment; Stock Edges HigherOne-Time Loss Impact - newsline.com
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
[Form 4] Vor Biopharma Inc. Insider Trading Activity - Stock Titan
Vor Biopharma (VOR) director receives 53,283 stock options at $14.09 strike - Stock Titan
Vor Biopharma (VOR) grants Alexander Cumbo 56,345 stock options - Stock Titan
Vor Biopharma (NASDAQ: VOR) updates and wins approval for 2021 equity plan - Stock Titan
Vor Biopharma (VOR) Stages 3.12% Rally: Potential Breakout Above $15.26 in Sight?Jelly Roll Trade - newsline.com
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
보 바이오파마 주식 (VOR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 17 '26 |
Sale |
16.28 |
458,411 |
7,462,931 |
2,739,208 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 20 '26 |
Sale |
15.77 |
171,963 |
2,711,857 |
2,567,245 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 13 '26 |
Sale |
16.15 |
530,610 |
8,569,352 |
3,404,998 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 14 '26 |
Sale |
15.97 |
153,735 |
2,455,148 |
3,251,263 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 15 '26 |
Sale |
16.01 |
53,644 |
858,840 |
3,197,619 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 08 '26 |
Sale |
16.48 |
484,104 |
7,977,786 |
4,071,637 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 09 '26 |
Sale |
16.59 |
135,201 |
2,242,985 |
3,936,436 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 10 '26 |
Sale |
15.75 |
828 |
13,041 |
3,935,608 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 06 '26 |
Sale |
16.59 |
589,257 |
9,777,898 |
4,555,741 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 02 '26 |
Sale |
18.23 |
260,000 |
4,741,066 |
5,144,998 |
2.64%
자본화:
|
볼륨(24시간):